Journal article
Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry
The American heart journal, Vol.225, pp.88-96
07/01/2020
DOI: 10.1016/j.ahj.2020.04.018
PMCID: PMC7539544
PMID: 32485329
Abstract
Background: Intensive lipid management is critical to reduce cardiovascular (CV) risk for patients with diabetes mellitus (DM).
Methods: We performed an observational study of 7628 patients with (n = 2943) and without DM (n = 4685), enrolled in the Provider Assessment of Lipid Management (PALM) registry and treated at 140 outpatient clinics across the United States in 2015. Patient self-estimated CV risk, patient-perceived statin benefit and risk, observed statin therapy use and dosing were assessed.
Results: Patients with DM were more likely to believe that their CV risk was elevated compared with patients without DM (39.1% vs 29.3%, P < .001). Patients with DM were more likely to receive a statin (74.2% vs 63.5%, P < .001) but less likely to be treated with guideline-recommended statin intensity (36.5% vs 46.9%, P < .001), driven by the low proportion (16.5%) of high risk (ASCVD risk >= 7.5%) primary prevention DM patients treated with a high intensity statin. Patients with DM treated with guideline-recommended statin intensity were more likely to believe they were at high CV risk (44.9% vs 38.4%, P = .005) and that statins can reduce this risk (41.1% vs 35.6%, P = .02), compared with patients treated with lower than guideline-recommended statin intensity. Compared with patients with an elevated HgbA1c, patients with well-controlled DM were no more likely to be on a statin (77.9% vs 79.3%, P = .43).
Conclusions: In this nationwide study, the majority of patients with DM were treated with lower than guideline-recommended statin intensity. Patient education and engagement may help providers improve lipid therapy for these high-risk patients.
Details
- Title: Subtitle
- Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry
- Creators
- Angela Lowenstern - Duke UniversityShuang Li - Duke UniversitySalim S. Virani - Baylor College of MedicineAnn Marie Navar - Duke UniversityZhuokai Li - Duke UniversityJennifer G. Robinson - University of IowaVeronique L. Roger - Mayo ClinicAnne C. Goldberg - Washington University in St. LouisAndrew Koren - Sanofi (France)Michael J. Louie - Regeneron (United States)Eric D. Peterson - Duke UniversityTracy Y. Wang - Duke University
- Resource Type
- Journal article
- Publication Details
- The American heart journal, Vol.225, pp.88-96
- DOI
- 10.1016/j.ahj.2020.04.018
- PMID
- 32485329
- PMCID
- PMC7539544
- NLM abbreviation
- Am Heart J
- ISSN
- 0002-8703
- eISSN
- 1097-6744
- Publisher
- Elsevier
- Number of pages
- 9
- Grant note
- Regeneron Pharmaceuticals; Regeneron Sanofi
- Language
- English
- Date published
- 07/01/2020
- Academic Unit
- Epidemiology; Fraternal Order of Eagles Diabetes Research Center
- Record Identifier
- 9984363625202771
Metrics
23 Record Views